Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 40 | 2025 | 176 | 11.460 |
Why?
|
| Infant, Very Low Birth Weight | 33 | 2022 | 169 | 7.690 |
Why?
|
| Intensive Care Units, Neonatal | 35 | 2025 | 187 | 6.790 |
Why?
|
| Breast Feeding | 29 | 2025 | 150 | 6.220 |
Why?
|
| Mothers | 22 | 2025 | 172 | 5.400 |
Why?
|
| Infant, Premature | 34 | 2025 | 190 | 4.870 |
Why?
|
| Infant, Newborn | 57 | 2025 | 588 | 4.330 |
Why?
|
| Enterocolitis, Necrotizing | 13 | 2022 | 45 | 2.570 |
Why?
|
| Lactation | 10 | 2021 | 51 | 2.440 |
Why?
|
| Milk Banks | 7 | 2020 | 22 | 2.320 |
Why?
|
| Infant | 24 | 2025 | 529 | 2.130 |
Why?
|
| Infant Nutritional Physiological Phenomena | 13 | 2025 | 68 | 2.090 |
Why?
|
| Gestational Age | 13 | 2025 | 80 | 1.970 |
Why?
|
| Infant, Premature, Diseases | 6 | 2020 | 30 | 1.910 |
Why?
|
| Enteral Nutrition | 6 | 2022 | 58 | 1.820 |
Why?
|
| Patient Discharge | 6 | 2025 | 136 | 1.580 |
Why?
|
| Child Development | 5 | 2020 | 67 | 1.460 |
Why?
|
| Infant Formula | 4 | 2020 | 22 | 1.430 |
Why?
|
| Female | 50 | 2025 | 14273 | 1.400 |
Why?
|
| Breast Milk Expression | 10 | 2020 | 41 | 1.260 |
Why?
|
| Humans | 63 | 2025 | 25692 | 1.240 |
Why?
|
| Intensive Care, Neonatal | 6 | 2019 | 31 | 1.160 |
Why?
|
| Residence Characteristics | 2 | 2019 | 183 | 1.070 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 277 | 0.910 |
Why?
|
| Gastroschisis | 2 | 2020 | 4 | 0.860 |
Why?
|
| Retrospective Studies | 15 | 2025 | 3220 | 0.820 |
Why?
|
| Health Care Costs | 4 | 2020 | 75 | 0.810 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2016 | 18 | 0.740 |
Why?
|
| Vitamin D | 1 | 2021 | 40 | 0.730 |
Why?
|
| Infant, Low Birth Weight | 2 | 2019 | 18 | 0.720 |
Why?
|
| Social Support | 2 | 2019 | 188 | 0.700 |
Why?
|
| Birth Weight | 7 | 2022 | 43 | 0.700 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 27 | 0.700 |
Why?
|
| Male | 31 | 2025 | 13917 | 0.680 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 74 | 0.670 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 11 | 0.660 |
Why?
|
| Diet | 3 | 2022 | 207 | 0.660 |
Why?
|
| Infant Care | 2 | 2016 | 16 | 0.650 |
Why?
|
| Prospective Studies | 12 | 2021 | 1633 | 0.630 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 46 | 0.630 |
Why?
|
| Pregnancy | 4 | 2025 | 291 | 0.630 |
Why?
|
| Oxidative Stress | 2 | 2018 | 93 | 0.620 |
Why?
|
| Anxiety | 1 | 2019 | 150 | 0.610 |
Why?
|
| Nervous System | 1 | 2017 | 10 | 0.570 |
Why?
|
| Stress, Psychological | 1 | 2019 | 211 | 0.570 |
Why?
|
| Maternal Behavior | 1 | 2017 | 11 | 0.560 |
Why?
|
| Pregnancy in Adolescence | 1 | 2017 | 13 | 0.560 |
Why?
|
| Adult | 14 | 2025 | 7336 | 0.540 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 201 | 0.540 |
Why?
|
| Quality of Health Care | 1 | 2017 | 117 | 0.510 |
Why?
|
| Quality Improvement | 1 | 2017 | 132 | 0.510 |
Why?
|
| Depression | 1 | 2019 | 412 | 0.510 |
Why?
|
| Informed Consent | 1 | 2015 | 21 | 0.510 |
Why?
|
| Sepsis | 2 | 2017 | 119 | 0.500 |
Why?
|
| Bacteria | 1 | 2016 | 72 | 0.500 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 49 | 0.500 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 31 | 0.500 |
Why?
|
| United States | 5 | 2025 | 1943 | 0.490 |
Why?
|
| Hospitalization | 3 | 2020 | 292 | 0.490 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 164 | 0.480 |
Why?
|
| Decision Making | 1 | 2015 | 203 | 0.440 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 167 | 0.430 |
Why?
|
| Educational Status | 4 | 2019 | 271 | 0.420 |
Why?
|
| Oxygen | 2 | 2003 | 74 | 0.390 |
Why?
|
| Tissue Donors | 3 | 2021 | 61 | 0.370 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 847 | 0.340 |
Why?
|
| Sleep | 2 | 2003 | 316 | 0.320 |
Why?
|
| Nutritive Value | 2 | 2020 | 24 | 0.320 |
Why?
|
| Nutritional Status | 2 | 2020 | 58 | 0.320 |
Why?
|
| Cohort Studies | 8 | 2022 | 1781 | 0.280 |
Why?
|
| Age Factors | 2 | 2020 | 716 | 0.270 |
Why?
|
| Child Language | 2 | 2017 | 19 | 0.270 |
Why?
|
| Incidence | 7 | 2020 | 731 | 0.270 |
Why?
|
| Goals | 2 | 2017 | 36 | 0.260 |
Why?
|
| Infant, Extremely Premature | 2 | 2022 | 9 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 333 | 0.260 |
Why?
|
| Qualitative Research | 2 | 2017 | 116 | 0.260 |
Why?
|
| Bottle Feeding | 2 | 2016 | 15 | 0.260 |
Why?
|
| Anthropometry | 1 | 2005 | 36 | 0.250 |
Why?
|
| Bedding and Linens | 2 | 2003 | 6 | 0.250 |
Why?
|
| Carbon Dioxide | 2 | 2003 | 17 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 259 | 0.240 |
Why?
|
| Infant, Extremely Low Birth Weight | 2 | 2017 | 19 | 0.230 |
Why?
|
| Motor Activity | 2 | 2017 | 304 | 0.230 |
Why?
|
| Child | 5 | 2022 | 1277 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1300 | 0.220 |
Why?
|
| Risk Factors | 4 | 2017 | 2224 | 0.220 |
Why?
|
| Postpartum Period | 2 | 2021 | 17 | 0.210 |
Why?
|
| Prone Position | 1 | 2003 | 33 | 0.210 |
Why?
|
| Maternal Age | 2 | 2019 | 14 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 124 | 0.200 |
Why?
|
| Young Adult | 5 | 2019 | 1855 | 0.190 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 71 | 0.190 |
Why?
|
| Respiration | 1 | 2001 | 32 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 12 | 0.180 |
Why?
|
| Arachidonic Acid | 1 | 2021 | 14 | 0.180 |
Why?
|
| Time Factors | 3 | 2018 | 1336 | 0.180 |
Why?
|
| Directive Counseling | 2 | 2019 | 13 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2021 | 62 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 13 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2020 | 18 | 0.180 |
Why?
|
| Premature Birth | 1 | 2020 | 11 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 24 | 0.180 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 119 | 0.180 |
Why?
|
| Intestinal Atresia | 1 | 2020 | 1 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 311 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2020 | 25 | 0.170 |
Why?
|
| Linear Models | 2 | 2017 | 231 | 0.170 |
Why?
|
| Intestinal Mucosa | 2 | 2018 | 178 | 0.160 |
Why?
|
| Contraception Behavior | 1 | 2019 | 5 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 299 | 0.160 |
Why?
|
| Inflammation | 2 | 2018 | 261 | 0.160 |
Why?
|
| Social Class | 1 | 2019 | 64 | 0.150 |
Why?
|
| Cognition | 2 | 2017 | 1265 | 0.150 |
Why?
|
| Chicago | 3 | 2016 | 869 | 0.150 |
Why?
|
| Food, Fortified | 1 | 2018 | 9 | 0.150 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 7 | 0.150 |
Why?
|
| Cell Death | 1 | 2018 | 40 | 0.150 |
Why?
|
| Length of Stay | 1 | 2020 | 300 | 0.150 |
Why?
|
| Energy Intake | 1 | 2018 | 72 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 11 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 284 | 0.150 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2017 | 2 | 0.150 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 7 | 0.140 |
Why?
|
| Protective Factors | 1 | 2017 | 27 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2017 | 56 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 52 | 0.140 |
Why?
|
| Probiotics | 1 | 2017 | 19 | 0.140 |
Why?
|
| Oligosaccharides | 1 | 2017 | 15 | 0.140 |
Why?
|
| Peer Group | 1 | 2017 | 35 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 39 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 124 | 0.130 |
Why?
|
| Bacteremia | 1 | 2017 | 94 | 0.130 |
Why?
|
| Anemia | 1 | 2017 | 88 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 39 | 0.130 |
Why?
|
| Phylogeny | 1 | 2016 | 42 | 0.130 |
Why?
|
| Illinois | 1 | 2016 | 223 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 44 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 50 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2013 | 44 | 0.130 |
Why?
|
| Feces | 1 | 2016 | 103 | 0.130 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2015 | 4 | 0.120 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 15 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2015 | 111 | 0.120 |
Why?
|
| Adolescent | 3 | 2017 | 2076 | 0.120 |
Why?
|
| Cost Savings | 1 | 2015 | 36 | 0.120 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 7 | 0.110 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 2 | 0.110 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.110 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 7 | 0.110 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Feeding Methods | 1 | 2013 | 4 | 0.110 |
Why?
|
| Propensity Score | 1 | 2013 | 32 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 33 | 0.100 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2012 | 6 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2013 | 59 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2003 | 5 | 0.100 |
Why?
|
| Direct Service Costs | 1 | 2012 | 4 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 27 | 0.100 |
Why?
|
| Tidal Volume | 2 | 2003 | 13 | 0.100 |
Why?
|
| Pediatrics | 1 | 2012 | 38 | 0.100 |
Why?
|
| Sudden Infant Death | 2 | 2003 | 37 | 0.100 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Codon, Terminator | 1 | 2011 | 3 | 0.100 |
Why?
|
| Biomarkers | 3 | 2020 | 554 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2012 | 60 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 2 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 532 | 0.090 |
Why?
|
| Fluconazole | 1 | 2010 | 8 | 0.090 |
Why?
|
| Cultured Milk Products | 1 | 2009 | 3 | 0.090 |
Why?
|
| Mycoses | 1 | 2010 | 21 | 0.090 |
Why?
|
| Milk | 1 | 2009 | 14 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 26 | 0.090 |
Why?
|
| Animals | 5 | 2020 | 3510 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2010 | 43 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 392 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 351 | 0.070 |
Why?
|
| Ventricular Pressure | 1 | 1996 | 2 | 0.070 |
Why?
|
| Lidocaine | 1 | 1996 | 21 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 35 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 76 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 177 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2003 | 7 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 9 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 24 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 32 | 0.050 |
Why?
|
| Polysomnography | 1 | 2003 | 72 | 0.050 |
Why?
|
| Face | 1 | 2003 | 19 | 0.050 |
Why?
|
| Air | 1 | 2001 | 4 | 0.050 |
Why?
|
| Methods | 1 | 2001 | 10 | 0.050 |
Why?
|
| Environment | 1 | 2001 | 42 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 12 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2020 | 2 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2020 | 3 | 0.050 |
Why?
|
| Choroid Diseases | 1 | 2020 | 3 | 0.050 |
Why?
|
| Retinal Diseases | 1 | 2020 | 4 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2020 | 19 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 10 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2001 | 22 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 28 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 68 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2001 | 66 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 396 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 124 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 419 | 0.040 |
Why?
|
| Intention | 1 | 2019 | 22 | 0.040 |
Why?
|
| Oceania | 1 | 2018 | 3 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 10 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 11 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 290 | 0.040 |
Why?
|
| North America | 1 | 2018 | 42 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 64 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 11 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 24 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 329 | 0.040 |
Why?
|
| Weight Gain | 1 | 2018 | 62 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 48 | 0.040 |
Why?
|
| Income | 1 | 2018 | 78 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 108 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 54 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 182 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 126 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3231 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 244 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 190 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 640 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 366 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 292 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 57 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1689 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 9 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2015 | 11 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 16 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 96 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 201 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2001 | 827 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 268 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 75 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 618 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 50 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 2 | 0.030 |
Why?
|
| Ampicillin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Gentamicins | 1 | 2013 | 13 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2013 | 18 | 0.030 |
Why?
|
| Cardiology | 1 | 2012 | 52 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 97 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 140 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 146 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2011 | 88 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 91 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 17 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 1345 | 0.020 |
Why?
|
| Cholestasis | 1 | 2010 | 10 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 22 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 410 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 913 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 739 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1996 | 14 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 11 | 0.020 |
Why?
|
| Sodium Channels | 1 | 1996 | 14 | 0.020 |
Why?
|
| Verapamil | 1 | 1996 | 24 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 32 | 0.020 |
Why?
|
| Models, Biological | 1 | 1996 | 311 | 0.010 |
Why?
|
| Lymphoma | 1 | 2001 | 30 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 163 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 169 | 0.010 |
Why?
|